Background

Narrow-band ultraviolet B (NB-UVB) is a first-line therapy for stage I mycosis fungoides (MF), with a complete response in 75%-85% of patients. However, data on long-term disease-free survival (DFS) after therapy are scarce.

Objective

To assess the long-term DFS after NB-UVB treatment of stage I MF.

Methods

We used a historic cohort of all stage I MF patients achieving a complete response with NB-UVB who discontinued treatment before 2011. Age at the beginning of phototherapy, sex, stage, skin phototype, number of treatments, total dose, and the length of DFS was collected.

Results

Of the 117 patients who started NB-UVB, 93 patients (80%) had a complete response and 56 (60%) were disease free as of March 2017. In a multivariate analysis, DFS was affected independently by age and disease stage only. DFS was longer for patients <50 years old (124 months) than those ≥50 years old (91 months, P = .01) and longer for stage IA patients (131 months) than stage IB patients (87.6 months, P = .001).

Limitations

The study was retrospective in nature.

Conclusion

After a single course of NB-UVB, over a half of stage I MF patients achieved >5 years of DFS and were potentially cured. Thus, NB-UVB can be considered a disease-modifying therapy.

中文翻译：

---

窄带紫外线B在I期真菌病真菌病患者中诱发持续持久的完全缓解脱药的潜力。

背景

窄带紫外线B（NB-UVB）是I期真菌病真菌（MF）的一线治疗，对75％-85％的患者有完全缓解。但是，关于治疗后长期无病生存（DFS）的数据很少。

客观的

评估NB-UVB治疗I期MF后的长期DFS。

方法

我们使用了一项历史性队列研究，所有I期MF患者均在2011年之前终止了NB-UVB的治疗，并获得了完全缓解。光疗开始时的年龄，性别，分期，皮肤照相类型，治疗次数，总剂量和疗程DFS已收集。

结果

截至2017年3月，在开始NB-UVB的117例患者中，有93例（80％）完全缓解，56例（60％）无病。在多因素分析中，DFS仅受年龄和疾病阶段的影响。<50岁患者（124个月）的DFS比≥50岁患者（91个月，P  = .01）更长，IA期患者（131个月）比IB期患者（87.6个月，P  = .001 ）更长。）。

局限性

该研究本质上是回顾性的。

结论

经过一个疗程的NB-UVB治疗后，超过一半的I期MF患者获得了超过5年的DFS，并且有可能治愈。因此，NB-UVB可以被认为是一种缓解疾病的疗法。